Clinical Trial

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-25.
Status change: Not Yet Recruiting → Recruiting 2025-09-09
Trial Details
NCT Number NCT06947967
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions Lymphoma, T-Cell, Peripheral
Enrollment 224 participants
Start Date 2025-08-12
Primary Completion 2032-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-15